Structure Therapeutics Inc. - American Depositary Shares (NQ:GPCR)

22.44 -1.47 (-6.15%)

Delayed Quote Updated: 2:55 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Structure Therapeutics Inc. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >

Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations

August 07, 2025

Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the...

Via MarketMinute

Topics Economy

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors ↗

August 07, 2025

Eli Lilly's obesity drug data misses targets, boosting shares of Novo Nordisk, Viking, Structure, and Terns amid promising trial updates.

Via Benzinga

Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge. ↗

August 07, 2025

An analyst called the unexpected flop a "once-in-a-blue-moon" occasion for Eli Lilly's dominant weight-loss franchise.

Via Investor's Business Daily

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

August 06, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

June 20, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

May 29, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

May 08, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

April 17, 2025

Traders are paying attention to the gapping stocks in Thursday's session. Let's dive into which stocks are experiencing notable gaps.

Via Chartmill

uniQure, Hertz Global, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗

April 17, 2025

Via Benzinga

Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish ↗

April 15, 2025

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

Via Stocktwits

Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today ↗

April 14, 2025

Pfizer bows, but is not entirely out of the GLP-1 race.

Via The Motley Fool

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

The State of Weight Loss Drugs ↗

March 10, 2025

Via The Motley Fool

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. ↗

March 03, 2025

This is the drugmaker's first foray into weight-loss drugs. And it's not focusing on GLP-1.

Via Investor's Business Daily

Structure Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Highlights

February 27, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

Why Structure Therapeutics Stock Was Stumbling This Week ↗

February 14, 2025

Via The Motley Fool

Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

January 30, 2025

From Structure Therapeutics Inc.

Via GlobeNewswire

AI Pharma: 2 Paths to AI-Powered Drug Investment

January 28, 2025

AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.

Via MarketBeat

Topics Artificial Intelligence

Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗

January 09, 2025

Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.

Via Investor's Business Daily

Topics Artificial Intelligence Government

Viking Therapeutics, Structure Therapeutics Positioned As Key Pharma Partners For Weight Loss Products: Analyst ↗

January 06, 2025

JPMorgan highlights valuation resets for Viking and Structure Therapeutics, citing opportunities in T2D/obesity and competitive clinical data insights.

Via Benzinga

Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche ↗

December 18, 2024

Under the deal's terms, Hansoh Pharma receives $112 million up front and a potential $1.9 billion in milestone payments.

Via Investor's Business Daily

Heico, Corvus Pharmaceuticals, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

December 18, 2024

Via Benzinga

Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity

December 17, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf? ↗

December 16, 2024

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

Via Investor's Business Daily

Weight-Loss Drugs Don't Seem To Impress RFK Jr. Should Eli Lilly, Novo Nordisk Investors Worry? ↗

November 22, 2024

Robert F. Kennedy hasn't overtly commented on how he would handle GLP-1 drugs. But there are hints.

Via Investor's Business Daily

Structure Therapeutics to Participate in the Jefferies London Healthcare Conference

November 15, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

November 13, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces First Patients Dosed in Phase 2b ACCESS Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, GSBR-1290, for Obesity

November 13, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek® 2024

October 31, 2024

From Structure Therapeutics Inc.

Via GlobeNewswire

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition ↗

October 23, 2024

Roche reported a 9% increase in third-quarter sales, driven by strong performance from Ocrevus and Vabysmo. Roche also raised concerns over the Catalent acquisition.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.